CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
NCT ID: NCT03383965
Last Updated: 2017-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
20 participants
INTERVENTIONAL
2017-03-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICAR30 T cells
anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
ICAR30 T cells
T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICAR30 T cells
T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky or Lansky score \>50;
* Expected survival\>12 weeks;
* Hgb \> 8.0;
* FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
* LVEF≥50%;
* Creatinine\<2.5mg/dl;
* Bilirubin\<2.5mg/dl;
* ALT (alanine aminotransferase)/AST (aspartate aminotransferase)\<3 fold normal;
* Patients must sign an informed consent.
Exclusion Criteria
* Uncontrolled active infection including hepatitis B or C;
* HIV positive;
* Active clinically significant CNS dysfunction;
* Current use of systemic steroids;
* Heterogenous lymphocyte treatments within recent 6 months;
2 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Weifang People's Hospital
OTHER
Immune Cell, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiulian Sun
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Weifang People's Hospital
Weifang, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiulian Sun, M.D., Ph.D
Role: primary
Xuehong Ran, Doctor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CD30-targeting CAR-T
Identifier Type: -
Identifier Source: org_study_id